{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T09:55:05Z","timestamp":1792662905154,"version":"4.5.0"},"reference-count":53,"publisher":"Massachusetts Medical Society","issue":"12","license":[{"start":{"date-parts":[[2023,3,23]],"date-time":"2023-03-23T00:00:00Z","timestamp":1679529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.nejmgroup.org\/legal\/terms-of-use.htm"}],"funder":[{"DOI":"10.13039\/100013988","name":"Dermira Inc.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013988","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["N Engl J Med"],"published-print":{"date-parts":[[2023,3,23]]},"DOI":"10.1056\/nejmoa2206714","type":"journal-article","created":{"date-parts":[[2023,3,15]],"date-time":"2023-03-15T17:00:13Z","timestamp":1678899613000},"page":"1080-1091","source":"Crossref","is-referenced-by-count":352,"title":["Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis"],"prefix":"10.1056","volume":"388","author":[{"given":"Jonathan I.","family":"Silverberg","sequence":"first","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.","family":"Irvine","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Stein Gold","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Simpson","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yu","family":"Chu","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuqing","family":"Liu","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"Gontijo Lima","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreekumar G.","family":"Pillai","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Seneschal","sequence":"additional","affiliation":[{"name":"From the Department of Dermatology, George Washington University School of Medicine and Health Sciences, Washington, DC (J.I.S.); the Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York (E.G.-Y.); the Institute and Comprehensive Center for Inflammation Medicine, University of L\u00fcbeck, L\u00fcbeck, Germany (D.T.); the Department of Clinical Medicine, Trinity College Dublin, Dublin (A.D.I.); Dermatology Clinical Research, Henry Ford Health System, Detroit (L.S.G.); Oregon Medical Research Center (A.B.), and the Department of Dermatology, Oregon Health and Science University (E.L.S.) \u2014 both in Portland; the Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei (C.-Y.C.); Eli Lilly, Indianapolis (Z.L., R.G.L., S.G.P.); and the Department of Dermatology and Pediatric Dermatology, National Reference Center for Rare Skin Disorders, Hospital Saint-Andr\u00e9, Bordeaux University, Centre National de la Recherche Scientifique, ImmunoConce..."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"150","reference":[{"key":"e_1_3_5_2_2","doi-asserted-by":"publisher","DOI":"10.4168\/aair.2018.10.3.207"},{"key":"e_1_3_5_3_2","doi-asserted-by":"publisher","DOI":"10.2500\/aap.2019.40.4202"},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31286-1"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2222.2007.02679.x"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14167"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2018.05.007"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1346-8138.2006.00187.x"},{"key":"e_1_3_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2016.05.028"},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.10.010"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.4081\/dr.2012.e1"},{"key":"e_1_3_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.05.1241"},{"key":"e_1_3_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2019.04.020"},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.07.012"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19580"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2018.07.006"},{"key":"e_1_3_5_17_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.0025"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.08.005"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpsychores.2020.110347"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.05.003"},{"key":"e_1_3_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18296"},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.023"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.03.030"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.anai.2020.08.016"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14891"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14888"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.13911"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-017-0044-7"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.01.011"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1177\/1203475420982553"},{"key":"e_1_3_5_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.13954"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2016.09.037"},{"key":"e_1_3_5_33_2","first-page":"41","article-title":"Comparison of the affinity and in vitro activity of lebrikizumab, tralokinumab, and cendakimab.","volume":"30","author":"Okragly A","year":"2021","unstructured":"Okragly A, Ryuzoji A, Daniels M, Patel C, Benschop R. Comparison of the affinity and in vitro activity of lebrikizumab, tralokinumab, and cendakimab. Exp Dermatol 2021:30:Suppl 1:41-41. abstract.","journal-title":"Exp Dermatol"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.7573\/dic.2021-1-7"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S211032"},{"key":"e_1_3_5_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0079"},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.01.017"},{"key":"e_1_3_5_38_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.281053"},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207841"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1610020"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20810"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20945"},{"key":"e_1_3_5_43_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-019-00288-x"},{"key":"e_1_3_5_44_2","doi-asserted-by":"publisher","DOI":"10.1111\/all.15326"},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.013"},{"key":"e_1_3_5_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.01.001"},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1111\/exd.14389"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19574"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2018.12.018"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.05.029"},{"key":"e_1_3_5_51_2","unstructured":"Dupixent (dupilumab). Tarrytown NY: Regeneron Pharmaceuticals 2022 (package insert)."},{"key":"e_1_3_5_52_2","unstructured":"Adbry (tralokinumab). Ballerup Denmark: Leo Pharma 2022 (package insert)."},{"key":"e_1_3_5_53_2","doi-asserted-by":"crossref","unstructured":"Wulur I Van Horn RD Ryuzoji A et al. Lebrikizumab allows (interleukin) IL-13 membrane binding and subsequent internalization through IL-13 receptor alpha 2 (R\u03b12) [IL-13 decoy receptor]. Presented at the 4th Inflammatory Skin Disease Summit New York November 3\u20136 2021. abstract.","DOI":"10.26226\/m.62fa0091165d7b0019592ac8"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.5534"}],"container-title":["New England Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nejm.org\/doi\/pdf\/10.1056\/NEJMoa2206714","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T18:58:32Z","timestamp":1749668312000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.nejm.org\/doi\/10.1056\/NEJMoa2206714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,23]]},"references-count":53,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,3,23]]}},"alternative-id":["10.1056\/NEJMoa2206714"],"URL":"https:\/\/doi.org\/10.1056\/nejmoa2206714","relation":{},"ISSN":["0028-4793","1533-4406"],"issn-type":[{"value":"0028-4793","type":"print"},{"value":"1533-4406","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,23]]}}}